Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00393952 · ClinicalTrials.gov registry record · Phase 3
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma
A Phase 3 study of Asthma, sponsored by SkyePharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 557
- Enrollment target
- 20
- Study locations
NCT00393952: Completed Phase 3 study of Asthma, sponsored by SkyePharma.
NCT00393952 is a Phase 3 study of Asthma that has completed, run by SkyePharma. The registered enrollment target is 557 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00393952, a Phase 3 study of Asthma, has completed, sponsored by SkyePharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 557 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy and safety of the fixed combination asthma drug FlutiForm with its two components administered alone, fluticasone propionate and formoterol fumarate, and with placebo in adult and adolescent patients with moderate to severe asthma.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Fluticasone propionate/Formoterol fumarate 250/10
- DRUG Fluticasone propionate/Formoterol fumarate 100/10
- DRUG Fluticasone propionate 250
- DRUG Formoterol fumarate 10
Study Locations (20)
California
- Research Site - Burbank
- Research Site - Fresno
- Research Site - Long Beach
- Research Site - Los Angeles
- Research Center - Los Angeles
- Research Site - Los Angeles
- Research Site - Mission Viejo
- Research Site - Monterey Park
- Research Site - Palmdale
- Research Site - Sacramento
- Research Site - San Diego
- Research Site - San Diego
- Research Site - San Jose
Arizona
- Research Site - Glendale
- Research Center - Phoenix
- Research Site - Phoenix
- Research Site - Tucson
Arkansas
- Research Site - Jonesboro
- Research Site - Little Rock
Alabama
- Research Center - Pell City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 557 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
What the finished NCT00393952 record still lists
NCT00393952 is an interventional study that assigns participants to a tested intervention. The registered 557 participants enrollment target is mid-sized for trials with a published cap, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT00393952 names 20 study sites across 4 states, led by California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00393952 about?
NCT00393952 is a clinical study titled "New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma". The purpose of this study is to compare the efficacy and safety of the fixed combination asthma drug FlutiForm with its two components administered alone, fluticasone propionate and formoterol fumarate, and with placebo in adult and adolescent patients with moderate to severe asthma.
What is the current status of trial NCT00393952?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 557 participants. The study started on 2006-06. Estimated completion is 2008-04.
What conditions does trial NCT00393952 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00393952?
The interventions under investigation include: Placebo (DRUG), Fluticasone propionate/Formoterol fumarate 250/10 (DRUG), Fluticasone propionate/Formoterol fumarate 100/10 (DRUG), Fluticasone propionate 250 (DRUG), Formoterol fumarate 10 (DRUG).
Who is sponsoring clinical trial NCT00393952?
This trial is sponsored by SkyePharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00393952 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00393952's enrollment target sits among peer trials
557 74th of 374 higher than 301 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05708885 · 557 participants · NA
Striated Esophageal Motor Function Modulation in Health and Disease
- NCT07173751 · 558 participants · Phase 3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- NCT06074588 · 556 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
- NCT06693622 · 556 participants
Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia